Moneycontrol PRO
UPCOMING EVENT:Moneycontrol Pro & Espresso presents Nifty Banker 2.0 - India's First Retail Index Traders Online Conference. 12 Webinars at Early bird offer of just Rs.50/- per webinar exclusive for Moneycontrol Pro subscribers. Register now!
you are here: HomeNewsBusiness

Granules India gets tentative nod from USFDA for generic Colchicine capsules

The US Food and Drug Administration (USFDA) has tentatively approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals Inc for Colchicine capsules in the strength of 0.6 mg, Granules India said in a filing to the BSE.

February 11, 2020 / 03:47 PM IST
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Granules India on Tuesday said it has received tentative approval from the US health regulator for its generic Colchicine capsules indicated for prevention of gout flares in adults.

The US Food and Drug Administration (USFDA) has tentatively approved the abbreviated new drug application (ANDA) filed by Granules Pharmaceuticals Inc for Colchicine capsules in the strength of 0.6 mg, Granules India said in a filing to the BSE.

The company's product is a generic version of Hikma International Pharmaceuticals LLC's Mitigare capsules in the same strength, it added.

"We are pleased to receive tentative approval for our fourth Paragraph IV ANDA and launch of the product will be as per our agreement with Hikma Pharmaceuticals USA Inc," Granules Pharmaceuticals Inc ED Priyanka Chigurupati said.

According to IQVIA Health data, the Mitigare brand and generic had US sales of around USD 84 million MAT for the 12 months ended December 2019, Granules India said.

Close
Shares of Granules India were trading at Rs 163.80 per scrip on the BSE, down 0.73 per cent from the previous close.
PTI
first published: Feb 11, 2020 03:37 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark